Arkolith/Insider Trading/TERN/Form 4

Burroughs Amy L.

Chief Executive Officer, DirectorTerns Pharmaceuticals, Inc. (TERN) · full profile →Form 4 · filed Feb 18, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$572K
Net Open-Market Flow
-$572K
Transactions
5
4 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 17, 2026Sell(S)4K$39.80$163K289K
Feb 17, 2026Sell(S)8K$39.22$320K293K
Feb 17, 2026Sell(S)2K$38.07$89K301K
Feb 17, 2026Option exercise(M)15K$4.64$68K304K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 17, 2026Option exercise(M)15K—$0970K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001872564-26-000006) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML